Alexander Esterhazy - CEL SCI Independent Director
| CVM Stock | USD 1.50 0.02 1.32% |
Director
Mr. Alexander G. Esterhazy is an Independent Director of CELSCI Corporationrationration. He was a Director of CELSCI since December 1999 and was an independent financial advisor since November 1997. Between July 1991 and October 1997, Mr. Esterhazy was a senior partner of Corporationrationfina S.A. Geneva, a firm engaged in mergers, acquisitions and portfolio management. Between January 1988 and July 1991, Mr. Esterhazy was a managing director of DG Bank in Switzerland. During this period Mr. Esterhazy was in charge of the Geneva, Switzerland branch of the DG Bank, founded and served as Vice President of DG Finance and was the President and Chief Executive Officer of DGBourse, a securities brokerage firm. Mr. Esterhazy brings extensive financial expertise that is valuable to CELSCI. since 1999.
| Age | 72 |
| Tenure | 25 years |
| Address | 8229 Boone Boulevard, Vienna, VA, United States, 22182 |
| Phone | 703 506 9460 |
| Web | https://cel-sci.com |
CEL SCI Management Efficiency
The company has Return on Asset of (0.5171) % which means that on every $100 spent on assets, it lost $0.5171. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (1.5825) %, meaning that it generated no profit with money invested by stockholders. CEL SCI's management efficiency ratios could be used to measure how well CEL SCI manages its routine affairs as well as how well it operates its assets and liabilities. As of the 19th of April 2024, Return On Tangible Assets is likely to drop to -1. In addition to that, Return On Capital Employed is likely to drop to -1.52. At this time, CEL SCI's Debt To Assets are very stable compared to the past year.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Gregory Hradsky | Cyclacel Pharmaceuticals | 54 | |
| Juergen Ernst | Aeterna Zentaris | 77 | |
| Shalini Sharp | Agenus Inc | 42 | |
| Nancy Hutson | BioCryst Pharmaceuticals | 68 | |
| Robert Spiegel | Cyclacel Pharmaceuticals | 68 | |
| Robert Ingram | BioCryst Pharmaceuticals | 75 | |
| Allison JeynesEllis | Agenus Inc | 52 | |
| Theresa Heggie | BioCryst Pharmaceuticals | 58 | |
| Pierre Lapalme | Aeterna Zentaris | 75 | |
| Gill Christie | Cyclacel Pharmaceuticals | 67 | |
| Samuel Barker | Cyclacel Pharmaceuticals | 75 | |
| Lloyd Sems | Cyclacel Pharmaceuticals | 44 | |
| Timothy Wright | Agenus Inc | 60 | |
| Brian MD | Cyclacel Pharmaceuticals | 61 | |
| Paul McBarron | Cyclacel Pharmaceuticals | 63 | |
| Ulf Wiinberg | Agenus Inc | 59 | |
| Kenneth Lee | BioCryst Pharmaceuticals | 70 | |
| Carolyn Egbert | Aeterna Zentaris | N/A | |
| Nicholas Bacopoulos | Cyclacel Pharmaceuticals | 64 | |
| John Banham | Cyclacel Pharmaceuticals | 76 | |
| Shahzad Malik | Agenus Inc | 46 | |
Management Performance
| Return On Equity | -1.58 | ||||
| Return On Asset | -0.52 |
CEL SCI Corp Leadership Team
Elected by the shareholders, the CEL SCI's board of directors comprises two types of representatives: CEL SCI inside directors who are chosen from within the company, and outside directors, selected externally and held independent of CEL. The board's role is to monitor CEL SCI's management team and ensure that shareholders' interests are well served. CEL SCI's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, CEL SCI's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Maximilian Clara, Founder, Chairman and Pres | ||
| Peter Young, Independent Director | ||
| Gavin Windt, IR Contact Officer | ||
| Geert Kersten, Chief Executive Officer, Treasurer, Director | ||
| Robert Watson, Independent Director | ||
| Alexander Esterhazy, Independent Director | ||
| John Cipriano, Senior Vice President - Regulatory Affairs | ||
| Patricia Prichep, Senior Vice President - Operations, Corporate Secretary | ||
| Bruno Baillavoine, Independent Director | ||
| Geert Esq, Treasurer Officer | ||
| Eyal Talor, Chief Scientific Officer | ||
| Daniel Zimmerman, Senior Vice President - Research, Cellular Immunology |
CEL Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is CEL SCI a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.58 | ||||
| Return On Asset | -0.52 | ||||
| Current Valuation | 85 M | ||||
| Shares Outstanding | 53.98 M | ||||
| Shares Owned By Insiders | 3.19 % | ||||
| Shares Owned By Institutions | 12.44 % | ||||
| Number Of Shares Shorted | 6.85 M | ||||
| Price To Earning | (1.14) X | ||||
| Price To Book | 6.96 X | ||||
| Price To Sales | 11,797 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards CEL SCI in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, CEL SCI's short interest history, or implied volatility extrapolated from CEL SCI options trading.
Pair Trading with CEL SCI
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if CEL SCI position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CEL SCI will appreciate offsetting losses from the drop in the long position's value.Moving against CEL Stock
| 0.75 | NUVB | Nuvation Bio Financial Report 2nd of May 2024 | PairCorr |
| 0.62 | IOVA | Iovance Biotherapeutics Financial Report 14th of May 2024 | PairCorr |
| 0.59 | ZNTL | Zentalis PharmaceuticalsL Financial Report 8th of May 2024 | PairCorr |
| 0.52 | JSPRW | Jasper Therapeutics | PairCorr |
| 0.43 | IMMP | Immutep Ltd ADR | PairCorr |
The ability to find closely correlated positions to CEL SCI could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace CEL SCI when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back CEL SCI - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling CEL SCI Corp to buy it.
The correlation of CEL SCI is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as CEL SCI moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if CEL SCI Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for CEL SCI can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CEL SCI Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Complementary Tools for CEL Stock analysis
When running CEL SCI's price analysis, check to measure CEL SCI's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CEL SCI is operating at the current time. Most of CEL SCI's value examination focuses on studying past and present price action to predict the probability of CEL SCI's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CEL SCI's price. Additionally, you may evaluate how the addition of CEL SCI to your portfolios can decrease your overall portfolio volatility.
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| CEOs Directory Screen CEOs from public companies around the world |
Is CEL SCI's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CEL SCI. If investors know CEL will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CEL SCI listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.69) | Revenue Per Share 0.001 | Quarterly Revenue Growth (0.63) | Return On Assets (0.52) | Return On Equity (1.58) |
The market value of CEL SCI Corp is measured differently than its book value, which is the value of CEL that is recorded on the company's balance sheet. Investors also form their own opinion of CEL SCI's value that differs from its market value or its book value, called intrinsic value, which is CEL SCI's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CEL SCI's market value can be influenced by many factors that don't directly affect CEL SCI's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CEL SCI's value and its price as these two are different measures arrived at by different means. Investors typically determine if CEL SCI is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CEL SCI's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.